Product was Cryoport’s largest product and service line in fiscal 2025, bringing in $79.68M of $176.18M (45%).
| Product and Service | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Product | $103.40M | $89.17M | $74.73M | $79.68M | |||||
| Biologistics Solutions | $124.80M | $65.91M | $67.02M | $78.14M | |||||
| Biopharmaceutical | — | — | — | — | |||||
| Biopharma/Pharma | — | — | — | — | |||||
| Biostorage/Bioservices | $9.08M | $13.59M | $15.03M | $18.36M | |||||
| Animal Health | — | — | — | — | |||||
| Reproductive Medicine | — | — | — | — | |||||
| Total | $237.28M | $168.66M | $156.77M | $176.18M |
Cryoport brought in $176.18M from its three product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 12.4% from $156.77M in fiscal 2024. Product was the largest at $79.68M (45.2%), ahead of Biologistics Solutions at $78.14M (44.4%) and Biostorage/Bioservices at $18.36M (10.4%).
Compared with fiscal 2024, Biostorage/Bioservices grew fastest, up 22.2% to $18.36M. Every line above 2% of revenue grew. From fiscal 2022 to 2025, combined revenue from these lines fell from $237.28M to $176.18M, a compound annual decline of 9.4%. Product's share of the total rose from 43.6% to 45.2%.
Americas was Cryoport’s largest region in fiscal 2025, bringing in $131.26M of $176.18M (75%).
| Geography | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Americas | $128.21M | $117.90M | $113.55M | $131.26M | |||||
| Emea | $66.91M | $27.65M | $27.02M | $25.13M | |||||
| Europe, The Middle East & Africa (Emea) | — | — | — | — | |||||
| Asia Pacific | $42.16M | $23.12M | $16.20M | $19.78M | |||||
| Asia Pacific (Apac) | — | — | — | — | |||||
| Total | $237.28M | $168.66M | $156.77M | $176.18M |
Cryoport brought in $176.18M from its three regions in fiscal 2025, the year ended December 31, 2025. That was up 12.4% from $156.77M in fiscal 2024. Americas was the largest at $131.26M (74.5%), ahead of Emea at $25.13M (14.3%) and Asia Pacific at $19.78M (11.2%).
Compared with fiscal 2024, Asia Pacific grew fastest, up 22.1% to $19.78M, while Emea fell the most, down 7.0% to $25.13M. From fiscal 2022 to 2025, combined revenue from these regions fell from $237.28M to $176.18M, a compound annual decline of 9.4%. Americas' share of the total rose from 54.0% to 74.5%.
Cryoport (CYRX) reports its revenue by product and service and by geography. In fiscal 2025, Product was its largest product and service line, bringing in $79.68M (45.2% of the total), followed by Biologistics Solutions at $78.14M (44.4%).
Product was Cryoport's largest product and service line in fiscal 2025, bringing in $79.68M, or 45.2% of the $176.18M total across its three product and service lines.
Americas was Cryoport's largest region in fiscal 2025, bringing in $131.26M, or 74.5% of the $176.18M total across its three regions.
Among Cryoport's product and service lines that make up at least 2% of revenue, Biostorage/Bioservices grew fastest in fiscal 2025, up 22.2% from $15.03M to $18.36M.
Every figure comes from Cryoport's annual financial filings, as reported. Each line keeps the name Cryoport gives it, and years follow its fiscal calendar.
Cryoport's revenue by product and service goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.